Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.48 |
| ▸ | IDH1 | O75874 | 3/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | NHERF1 | O14745 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23832727 | 0.89 | CA2 (0.48) | MEN1KMT2AMAPTLMNAIDH1 | |
| SCHEMBL30218187 | 0.89 | CA2 (0.48) | MEN1KMT2AMAPTLMNAIDH1 | |
| SCHEMBL30218156 | 0.88 | IDH1 (0.54) | MEN1KMT2AMAPTIDH1GAA | |
| SCHEMBL23832701 | 0.88 | IDH1 (0.54) | MEN1KMT2AMAPTIDH1GAA | |
| SCHEMBL30218226 | 0.86 | CA2 (0.46) | MEN1KMT2ATBXA2RIDH1ALDH1A1 | |
| SCHEMBL23832724 | 0.86 | CA2 (0.46) | MEN1KMT2ATBXA2RIDH1ALDH1A1 | |
| SCHEMBL23832738 | 0.86 | CA12 (0.61) | MEN1KMT2AMAPTLMNAIDH1 | |
| SCHEMBL30218167 | 0.86 | ALDH1A1 (0.53) | MEN1KMT2AMAPTLMNATBXA2R | |
| SCHEMBL23832758 | 0.86 | ALDH1A1 (0.53) | MEN1KMT2AMAPTLMNATBXA2R | |
| SCHEMBL23832730 | 0.84 | MOGAT2 (0.48) | MEN1KMT2AMAPTCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230174523-A1 | BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF | AMATHUS THERAPEUTICS, INC. (US) | 2023-06-08 | — | — | US | disclosed |
| US-20230174523-A1 | BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF | AMATHUS THERAPEUTICS, INC. (US) | 2023-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230174523-A1 | BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF | TRAP1, PINK1, TP53BP1 | MEN1 3902/4885KMT2A 4864/4885MAPT 89/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.